CD30/TNFRSF8
Alpha Lifetech can provide CD30/TNFRSF8 corresponding products, help each customer's research and development.
01
Introduction To CD30/TNFRSF8
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD30/TNFRSF8 protein is a common target in medicine.
CD30 is a transmembrane glycoprotein receptor, tumor necrosis factor receptor superfamily member 8 (TNFRSF8), which is mainly expressed on the surface of activated T cells, B cells, and NK cells, and has low expression levels in physiological conditions. In disease states, such as viral infections, autoimmune diseases, and various lymphomas, CD30 is expressed at high levels, with specific effects on tumor cell proliferation and function. CD30 consists mainly of the extracellular, transmembrane, and intracellular domains, and to bind the ligand, CD30 must form a trimeric structure consisting of three transmembrane CD30 strands.
Function of Target CD30/TNFRSF8
By binding to the CD30 ligand, CD30 can appear with bidirectional signals and activate the subsequent immune response of CD30, which can mediate various biological functions, including cell proliferation, activation, apoptosis, and so on. Abnormal expression of CD30 is closely related to the occurrence and progression of various diseases. Overexpression of CD30 protein is one of the typical features in Hodgkin's lymphoma. Moreover, CD30 is also expressed in other types of lymphoma, leukemia, as well as certain solid tumors.
Gene Pathway of Target CD30/TNFRSF8
The binding of the CD30 trimer to its ligand induces the trimerization of other transmembrane proteins, such as TRAF 1,2, and 5, which activate signal transduction and gene transcription of the MAPK / ERK 1 / ERK 2 pathway. After binding CD30 to its ligand, it forms a complex at the cell membrane and internalization occurs. The internalized CD30 complex activates a series of downstream signaling molecules, such as NF- κ B, STAT 3, and STAT 6. Activation of these signaling molecules can further affect the biological behavior of cells, such as proliferation, differentiation, and apoptosis. The CD30 signaling pathway promotes cell proliferation and inhibits apoptosis by activating related signaling molecules. This mechanism of action allows CD30 to play an important role in the growth and spread of tumor cells.
Fig 1: CD30 Gene Pathway. (Reference source: Nakashima M, Uchimaru K. CD30 Expression and Its Functions during the Disease Progression of Adult T-Cell Leukemia/Lymphoma. Int J Mol Sci. 2023 May 13;24(10):8731.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD30/TNFRSF8 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD30/TNFRSF8 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD30/TNFRSF8 protein products are also essential. Alpha Lifetech can provide CD30/TNFRSF8 corresponding products and help each customer's research and development. In addition, Alpha Lifetech also provides advanced expression systems and purification services to accelerate antibody research and development. Our synthesized antibody expression undergoes rigorous quality validation, including sequencing validation and functional expression analysis, to ensure high fidelity and performance. In addition, Alpha Lifetech provides customized solutions for recombinant proteins, such as codon optimization, promoter selection, and vector design, supplemented by downstream applications such as protein expression analysis to meet specific experimental needs.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64543 | 50ug,100ug,500ug | |
| ADT1324 | 1mg,5mg | |
Reference
[1] Nakashima M, Uchimaru K. CD30 Expression and Its Functions during the Disease Progression of Adult T-Cell Leukemia/Lymphoma. Int J Mol Sci. 2023 May 13;24(10):8731.
[2] Piotrowska M, Spodzieja M, Kuncewicz K, Rodziewicz-Motowidło S, Orlikowska M. CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions, and functions. Eur J Med Chem. 2021 Nov 15;224:113694.
[3] Le Bouteiller P, Tabiasco J, Polgar B, Kozma N, Giustiniani J, Siewiera J, Berrebi A, Aguerre-Girr M, Bensussan A, Jabrane-Ferrat N. CD160: a unique activating NK cell receptor. Immunol Lett. 2011 Aug 30;138(2):93-6.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102